Skip to main content
All lobbying filings

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. filed a Q2 report for Ionis Pharmaceuticals, Inc. on July 17, 2026.

Lobbying for Ionis Pharmaceuticals, Inc. · Biotechnology company.

As filed: IONIS PHARMACEUTICALS, INC. for IONIS PHARMACEUTICALS, INC.

All filings by Ionis Pharmaceuticals, Inc. · Everything Ionis Pharmaceuticals, Inc. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 17, 2026
Expenses
$150,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act.

Taxation/Internal Revenue Code

Issues related to the implementation of the Tax Cuts and Jobs Act of 2017. H.R.1414 - Camerons Law.

Health Issues

Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025. Issues related to drug pricing policy.

 Bills named in this filing 4
  • H.R. 1672
    Maintaining Investments in New Innovation Act
  • H.R. 1414
    Cameron’s Law
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
  • S. 932
    Give Kids a Chance Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem